About ACADIA Pharmaceuticals Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://acadia.com/
Frequently Asked Questions
What is the 52-week range for ACAD?
The 52-week high is $30.96 and the 52-week low is $19.69.
What is the P/E ratio for ACAD?
The Price to Earnings (P/E) ratio is 9.05.
What is the dividend yield for ACAD?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is 32.39%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is 33.42%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 3.68.
Analyst Recommendation Trends
Wall Street analyst consensus for ACAD over the last few months:
Latest ACAD News
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041
ACAD gains a potential patent extension for Daybue to 2041, while strong sales growth and EU approval expand trofinetide's reach.
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
SAN DIEGO, September 28, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/590,496, titled "Methods and Compositions for Treatment of Rett Syndrome." The Notice of Allowance indicates that the USPTO has determined that the application meets the requirements for patentability, and the patent is expected to issue following completion of standard administrati
Acadia Pharmaceuticals Announces USPTO Issued Notice Of Allowance For U.S. Patent Application No. 17/590,496, Titled “Methods and Compositions for Treatment of Rett Syndrome.”
https://acadia.com/en-us/media/news-releases/acadia-pharmaceuticals-announces-allowance-of-u-s--patent-covering-weight-banded-dosing-of-trofinetide-extending-u-s--patent-protections-to-march-2041
3 Stocks Put Traders Are Targeting Today: AMTX, ACAD, REZI
AMTX, ACAD, and REZI are drawing attention from options bears
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop
Acadia Pharmaceuticals has seen its share price fall sharply over the past month, and that pullback is pushing investors to ask whether the current valuation still lines up with what the business is earning today. With the stock under pressure and expectations around its drug pipeline shifting, the key issue is how much of those earnings are already reflected in the price. The share price is down 29.0% over the past month. That puts fresh focus on whether recent weakness has moved Acadia...
ACAD Stock Tumbles Today: Analysts Weigh RADIANT Results, Cut Price Targets
Acadia's latest trial update has put the spotlight on remlifanserin's development path, prompting analysts to reassess its near-term prospects and valuation.
ACAD Stock Down 13% as Phase II Alzheimer's Study Misses Primary Goal
Acadia stock falls 13% after its Alzheimer's psychosis study narrowly misses its primary goal, though 60 mg results support continued phase III development.
Acadia chugs on with Alzheimer’s psychosis programme despite Phase II miss
Acadia hopes to become one of the first companies to secure approval for a therapy specifically indicated for ADP.
Novo pursues long-acting obesity drugs; Acadia slumps on Alzheimer’s data
Novo’s latest alliance involves injectables given every one to three months. Elsewhere, Nektar won a legal spat with Eli Lilly and the FDA issued two approvals.
Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $31
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $38 to $31.
HC Wainwright & Co. Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33
HC Wainwright & Co. analyst Ananda Ghosh maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $37 to $33.
AMD To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Friday
Analysts cut targets for GWW, IE and COST, while raising targets for OKTA, AXGN, ZS and DRI; ratings remained unchanged.
Citizens Maintains Market Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $33
Citizens analyst Jason N. Butler maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Market Outperform and lowers the price target from $36 to $33.
BMO Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $34
BMO Capital analyst Evan David Seigerman maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Outperform and lowers the price target from $36 to $34.
Needham Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $35
Needham analyst Ami Fadia maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $41 to $35.
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13%
ACADIA Pharmaceuticals (NASDAQ:ACAD) fell for a fifth consecutive day on Thursday, shedding 12.78 percent to close at $22.18 apiece, after earning a sell recommendation from Goldman Sachs. In its market note, the investment firm reiterated its sell recommendation and $17 price target on the stock after missing its primary endpoint in its phase 2 study […]
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026
Key Stats for Acadia Pharmaceuticals StockToday’s Performance: -19%52-Week Range: $20 to $31Valuation Model Target Price: $34Implied Upside: 54%What Happened?Acadia Pharmaceuticals stock (NASDAQ: ACAD) is facing a major test over whether remlifanserin still has a credible path forward in Alzheimer’s disease psychosis after its Phase 2 trial narrowly missed its main goal. Remlifanserin is being developed to treat hallucinations and delusions associated with Alzheimer’s disease psychosis, an indic
ACAD Stock Clocks Worst Day In 2 Years After Alzheimer’s Psychosis Drug Misses Main Goal — Citi Cuts Drug’s Success Odds To 20%
Citi’s Yigal Nochomovitz trimmed his price target to $33 from $40 and kept a Buy rating following the company’s update.
Bears Chase Down Acadia Pharma After Surprise Alzheimer's Setback
Acadia stock tumbled Thursday after the company's experimental Alzheimer's disease psychosis treatment missed the mark in a Phase 2 study.
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks were higher late Thursday afternoon, with the NYSE Healthcare Index increasing 0.9
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis Transcript
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis September 24,...
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data
Shares of Acadia Pharmaceuticals (NASDAQ:ACAD) fell more than 9% Thursday morning after the company reported mixed Phase 2 results for remlifanserin, its experimental treatment for Alzheimer's disease psychosis. The once-daily 60 mg dose eased hallucinations and delusions more than placebo...
ACADIA Advances 60 mg Remlifanserin After Near-Miss in Alzheimer’s Psychosis Trial
ACADIA Pharmaceuticals (NASDAQ:ACAD) reported top-line results from the phase II portion of its RADIANT clinical program evaluating remlifanserin for hallucinations and delusions associated with Alzheimer’s disease psychosis, or ADP. The company said the 60 mg once-daily dose narrowly missed statist
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $33
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and lowers the price target from $40 to $33.
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint
Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) shares fell 6% after the company reported results from its Phase 2 RADIANT study of remlifanserin in Alzheimer’s disease psychosis, with the trial missing its primary endpoint while meeting a key secondary measure at nominal statistical significance.
Acadia Drug Misses Primary Goal in Alzheimer’s Related Psychosis
Acadia Pharmaceuticals reports Phase 2 remlifanserin trial results for Alzheimer’s psychosis and plans to move into Phase 3.
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease Psychosis - Slideshow
2026-09-24. The following slide deck was published by ACADIA Pharmaceuticals Inc.
Crude Oil Rises Over 4%; Darden Earnings Miss Views
U.S. stocks fell Thursday: Dow -0.7%, S&P 500 -0.46%, Nasdaq -0.7%. Oil jumped 4.4%; Darden missed estimates, while APUS surged 163%.
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint
ACADIA Pharmaceuticals' (ACAD) shares dropped 10% pre-bell after it reported that its phase 2 RADIAN
Acadia Pharmaceuticals: Remlifanserin Is In Trouble
I am not optimistic about remlifanserinâs phase 3 success, with a probability of success to 25% due to efficacy and trial concerns. Read the latest on Acadia Pharmaceuticals stock here.
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
SAN DIEGO, September 24, 2026--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced Phase 3 enabling topline results from the Phase 2 portion of the ongoing RADIANT clinical trial program evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis (ADP).
Needham Reiterates Buy on ACADIA Pharmaceuticals, Maintains $41 Price Target
Needham analyst Ami Fadia reiterates ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and maintains $41 price target.
Acadia’s Remlifanserin Advances Toward Phase 3 In Alzheimer’s Psychosis Despite Narrow Miss On Primary Endpoint
-- Meaningful and consistent efficacy trends across endpoints support continuing with Phase 3 development of 60 mg once daily remlifanserin in ADP, with demonstrated evidence of dose effect-- Narrowly missed primary
Acadia Pharmaceuticals Receives Preliminary Court Approval Of Settlement Of Kanner Et Al. V. Biggar Et Al. Derivative Action
On August 24, 2026, the United States District Court for the Southern District of California (the "Court") preliminarily approved the settlement ("Settlement") of the stockholder derivative action
Why Is Acadia (ACAD) Up 0.5% Since Last Earnings Report?
Acadia (ACAD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-08-06 | Schneyer Mark C. | -14,292 | - | - |
| 2026-08-06 | Schneyer Mark C. | -9,292 | $29.3375 | $272,604 |
| 2026-08-06 | Schneyer Mark C. | -5,000 | $29 | $145,000 |
| 2026-08-06 | Schneyer Mark C. | +14,292 | $17.84 | $254,969 |
| 2026-08-05 | Schneyer Mark C. | -5,849 | - | - |
| 2026-08-05 | Schneyer Mark C. | -5,849 | $29.0029 | $169,638 |
| 2026-08-05 | Schneyer Mark C. | +5,849 | $17.84 | $104,346 |
| 2026-07-30 | Thompson Elizabeth H.Z. | -50 | $26.17 | $1,309 |
| 2026-07-30 | Thompson Elizabeth H.Z. | -16,508 | $26.13 | $431,354 |
| 2026-07-29 | Thompson Elizabeth H.Z. | -32,272 | - | - |
| 2026-07-29 | Thompson Elizabeth H.Z. | +32,272 | - | - |
| 2026-05-29 | BAKER BROS. ADVISORS LP | +32,008 | - | - |
| 2026-05-29 | BAKER BROS. ADVISORS LP | +32,008 | - | - |
| 2026-05-29 | BAKER BROS. ADVISORS LP | +18,622 | - | - |
| 2026-05-29 | BAKER BROS. ADVISORS LP | +18,622 | - | - |
| 2026-05-29 | Ndu Adora | +9,311 | - | - |
| 2026-05-29 | Ndu Adora | +16,004 | - | - |
| 2026-05-29 | Ndu Adora | -8,107 | - | - |
| 2026-05-29 | Ndu Adora | +8,107 | - | - |
| 2026-05-29 | GAROFALO ELIZABETH A. | +9,311 | - | - |
| 2026-05-29 | GAROFALO ELIZABETH A. | +16,004 | - | - |
| 2026-05-29 | GAROFALO ELIZABETH A. | -8,107 | - | - |
| 2026-05-29 | GAROFALO ELIZABETH A. | +8,107 | - | - |
| 2026-05-29 | Poole Jonathan | +9,311 | - | - |
| 2026-05-29 | Poole Jonathan | +16,004 | - | - |
| 2026-05-29 | Poole Jonathan | -2,010 | - | - |
| 2026-05-29 | Poole Jonathan | +2,010 | - | - |
| 2026-05-29 | Daly James M | +9,311 | - | - |
| 2026-05-29 | Daly James M | +16,004 | - | - |
| 2026-05-29 | Daly James M | -8,107 | - | - |
| 2026-05-29 | Daly James M | +8,107 | - | - |
| 2026-05-29 | Brege Laura | +9,311 | - | - |
| 2026-05-29 | Brege Laura | +16,004 | - | - |
| 2026-05-29 | Brege Laura | -8,107 | - | - |
| 2026-05-29 | Brege Laura | +8,107 | - | - |
| 2026-05-29 | HARRIGAN EDMUND | +9,311 | - | - |
| 2026-05-29 | HARRIGAN EDMUND | +16,004 | - | - |
| 2026-05-29 | HARRIGAN EDMUND | -8,107 | - | - |
| 2026-05-29 | HARRIGAN EDMUND | +8,107 | - | - |
| 2026-05-26 | Kihara James | -5,401 | $21.18 | $114,393 |
| 2026-05-04 | Schneyer Mark C. | -3,506 | $21.79 | $76,396 |
| 2026-05-04 | Kihara James | -1,332 | $21.79 | $29,024 |
| 2026-05-01 | Schneyer Mark C. | -6,815 | - | - |
| 2026-05-01 | Schneyer Mark C. | +6,815 | - | - |
| 2026-05-01 | Kihara James | -2,596 | - | - |
| 2026-05-01 | Kihara James | +2,596 | - | - |
| 2026-04-07 | Schneyer Mark C. | -2,709 | $22.2 | $60,140 |
| 2026-04-07 | Kihara James | -1,030 | $22.2 | $22,866 |
| 2026-04-05 | Schneyer Mark C. | -5,276 | - | - |
| 2026-04-05 | Schneyer Mark C. | +5,276 | - | - |
| 2026-04-05 | Kihara James | -2,010 | - | - |
| 2026-04-05 | Kihara James | +2,010 | - | - |
| 2026-03-26 | Schneyer Mark C. | -37 | $21.7174 | $804 |
| 2026-03-26 | Schneyer Mark C. | -3,171 | $21.65 | $68,652 |
| 2026-03-26 | Kihara James | -12 | $21.7253 | $261 |
| 2026-03-26 | Kihara James | -1,097 | $21.65 | $23,750 |
| 2026-03-25 | Schneyer Mark C. | -6,178 | - | - |
| 2026-03-25 | Schneyer Mark C. | +6,178 | - | - |
| 2026-03-25 | Schneyer Mark C. | -4,177 | $21.47 | $89,680 |
| 2026-03-25 | Thompson Elizabeth H.Z. | -3,435 | $21.47 | $73,749 |
| 2026-03-25 | Owen Adams Catherine | -11,641 | $21.47 | $249,932 |
| 2026-03-25 | Kihara James | -2,142 | - | - |
| 2026-03-25 | Kihara James | +2,142 | - | - |
| 2026-03-25 | Kihara James | -833 | $21.47 | $17,885 |
| 2026-03-25 | Rhodes Jennifer J | -3,844 | $21.47 | $82,531 |
| 2026-03-24 | Schneyer Mark C. | -8,138 | - | - |
| 2026-03-24 | Schneyer Mark C. | +8,138 | - | - |
| 2026-03-24 | Thompson Elizabeth H.Z. | -6,715 | - | - |
| 2026-03-24 | Thompson Elizabeth H.Z. | +6,715 | - | - |
| 2026-03-24 | Owen Adams Catherine | -23,509 | - | - |
| 2026-03-24 | Owen Adams Catherine | +23,509 | - | - |
| 2026-03-24 | Kihara James | -1,627 | - | - |
| 2026-03-24 | Kihara James | +1,627 | - | - |
| 2026-03-24 | Rhodes Jennifer J | -7,515 | - | - |
| 2026-03-24 | Rhodes Jennifer J | +7,515 | - | - |
| 2026-03-06 | Garner Thomas | +28,493 | - | - |
| 2026-03-06 | Garner Thomas | +97,947 | - | - |
| 2026-03-06 | Schneyer Mark C. | +26,382 | - | - |
| 2026-03-06 | Schneyer Mark C. | +90,691 | - | - |
| 2026-03-06 | Thompson Elizabeth H.Z. | +29,548 | - | - |
| 2026-03-06 | Thompson Elizabeth H.Z. | +101,574 | - | - |
| 2026-03-06 | Owen Adams Catherine | +76,509 | - | - |
| 2026-03-06 | Owen Adams Catherine | +263,005 | - | - |
| 2026-03-06 | Kihara James | +6,332 | - | - |
| 2026-03-06 | Kihara James | +21,766 | - | - |
| 2026-03-06 | Rhodes Jennifer J | +26,382 | - | - |
| 2026-03-06 | Rhodes Jennifer J | +90,691 | - | - |
| 2026-03-03 | Poole Jonathan | +2,010 | - | - |
| 2026-03-03 | Poole Jonathan | +4,218 | - | - |
| 2026-03-03 | Poole Jonathan | +3,565 | - | - |
| 2026-03-03 | Poole Jonathan | +7,482 | - | - |
| 2026-02-09 | Rhodes Jennifer J | -6,950 | $23.38 | $162,491 |
| 2026-02-06 | Rhodes Jennifer J | -12,944 | - | - |
| 2026-02-06 | Rhodes Jennifer J | +12,944 | - | - |
| 2025-11-18 | Schneyer Mark C. | -10,262 | $23.6907 | $243,114 |
| 2025-11-18 | Kihara James | -4,084 | $23.6909 | $96,754 |
| 2025-11-17 | Schneyer Mark C. | -9,913 | - | - |
| 2025-11-17 | Schneyer Mark C. | -9,913 | - | - |
| 2025-11-17 | Schneyer Mark C. | +9,913 | - | - |
| 2025-11-17 | Schneyer Mark C. | +9,913 | - | - |
| 2025-11-17 | Kihara James | -3,966 | - | - |
| 2025-11-17 | Kihara James | -3,966 | - | - |
| 2025-11-17 | Kihara James | +3,966 | - | - |
| 2025-11-17 | Kihara James | +3,966 | - | - |
| 2025-11-10 | Daly James M | -30,000 | $22.3661 | $670,983 |